E96 H2== @7 E96 =2C86 :?E6DE:?6 W4@=@?X 42? 364@>6 >@C6 D6?D:E:G6 E92? FDF2=j :E 8@6D :?E@ DA2D> 27E6C @?=J >:=5 DE:>F=2E:@?]k^Am kA 4=2DDlQq@5Jr@AJQm\\ w6:89E6?65 D6?D:E:G:EJ] p?@E96C A@DD:3:=:EJ 😀 E92E A6@A=6 H:E9 xq$ 92G6 2 >F49 =@H6C E9C6D9@=5 7@C A2:? E92? A6@A=6 H:E9@FE xq$]k^Am kA 4=2DDlQq@5Jr@AJQm\\ w@C>@?6D AC@5F465 😕 E96 vx EC24E[ H9:49 27764E >@G6>6?E @7 E96 3@H6=D[ >2J 2=D@ EC:886C DJ>AE@>D] (@>6? H:E9 xq$ @7E6? 92G6 >@C6 DJ>AE@>D 5FC:?8 E96:C >6?DECF2= A6C:@5D] %9:D DF886DED E92E =6G6=D @7 C6AC@5F4E:G6 9@C>@?6D 2=D@ 27764E xq$ DJ>AE@>D]k^Am kA 4=2DDlQq@5Jr@AJQm\\ s:6E2CJ 724E@CD] r6CE2:? 7@@5D 42? EC:886C xq$ DJ>AE@>D] r@>>@? 4F=AC:ED :?4=F56 4233286[ 3C@44@=:[ =68F>6D 2?5 @E96C 82D\AC@5F4:?8 7@@5D[ 42776:?6[ 2=4@9@=[ 52:CJ AC@5F4ED[ 72EEJ 7@@5D[ C2H 7CF:ED[ 2?5 7@@5D[ 8F>D 2?5 36G6C286D 4@?E2:?:?8 D@C3:E@=[ 2?
New Drug Shows Promise in Treating Diarrhea-Associated Irritable Bowel Syndrome
Assessments of participants quality of life using the 34-item Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire were completed 2 weeks before and 12 weeks after the start of treatment. Baseline IBS-QOL total scores averaged 53.2 points on a 100-point scale. Based on previous research, investigators defined a 14-point improvement in symptoms on the IBS-QOL scale as the minimally clinically relevant improvement.4 A clinically relevant improvement in IBS-QOL scores occurred in 48% of placebo-treated patients and a greater portion (more than 65%) of patients receiving eluxadoline at a dosage of 100 mg daily (number needed to treat [NNT] 6). A much greater, 22-point, improvement occurred in 25% of patients receiving placebo compared with more than 47% of patients receiving 100-mg eluxadoline daily (NNT 5).4 Eluxadoline acts as a mu opioidreceptor agonist and delta opioidreceptor antagonist. According to Furiex, the most common adverse events observed with the medications use include nausea, vomiting, and abdominal pain. However, these adverse events occurred in a similar portion of patients receiving placebo.5 Fred Eshelman, founder and chairmen of Furiex, has predicted that if eluxadoline is approved, it will generate annual sales totaling $750 million to $1 billion.1 References 1. Furiex irritable bowel syndrome drug succeeds in large trials. Reuters website. http://www.reuters.com/article/2014/02/04/furiex-bowel-idINL2N0L81RK20140204. Accessed February 2014. 2. Efficacy, safety, and tolerability of JNJ-27018966 in the treatment of patients with diarrhea-predominant irritable bowel syndrome (IBS-d) (protocol JNJ-27018966IBS3001). http://clinicaltrials.gov/ct2/show/NCT01553591.